This HTML5 document contains 65 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00439/identifier/chemspider/
n16http://linked.opendata.cz/resource/mesh/concept/
n18http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00439/identifier/chebi/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00439/identifier/wikipedia/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00439/identifier/pharmgkb/
n7http://bio2rdf.org/drugbank:
n23http://linked.opendata.cz/resource/drugbank/drug/DB00439/identifier/pdb/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00439/identifier/kegg-compound/
admshttp://www.w3.org/ns/adms#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00439/identifier/bindingdb/
n11http://www.drugs.com/mtm/
n17http://www.rxlist.com/cgi/generic/
n4http://linked.opendata.cz/resource/drugbank/drug/DB00439/identifier/pubchem-compound/
n9http://linked.opendata.cz/resource/drugbank/patent/
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n15http://linked.opendata.cz/ontology/mesh/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00439/identifier/pubchem-substance/
n5http://linked.opendata.cz/ontology/drugbank/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00439/identifier/drugbank/
n8http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB00439
rdf:type
n5:Drug
n5:description
On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal Rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market.
n5:generalReferences
# Furberg CD, Pitt B: Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2001;2(5):205-207. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11806796
n5:group
withdrawn
n5:halfLife
2-3 hours
n5:indication
Used as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb) when the response to dietary restriction of saturated fat and cholesterol and other non-pharmacological measures alone has been inadequate.
n5:manufacturer
n18:271B4EF2-363D-11E5-9242-09173F13E4C5
owl:sameAs
n7:DB00439 n14:DB00439
dcterms:title
Cerivastatin
adms:identifier
n4:446156 n13:Cerivastatin n19:3558 n20:393588 n21:18376 n22:C07966 n23:116 n24:DB00439 n25:46505877 n26:PA448897
n5:mechanismOfAction
Cerivastatin competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the hepatic enzyme responsible for converting HMG-CoA to mevalonate. As mevalonate is a precursor of sterols such as cholesterol, this results in a decrease in cholesterol in hepatic cells, upregulation of LDL-receptors, and an increase in hepatic uptake of LDL-cholesterol from the circulation.
n5:packager
n18:271B4EF1-363D-11E5-9242-09173F13E4C5
n5:patent
n9:2057444 n9:5177080 n9:1340798
n5:toxicity
Rhabdomyolysis, liver concerns
n5:foodInteraction
Take without regard to meals. Grapefruit and grapefruit juice should be avoided throughout treatment as grapefruit can significantly increase serum levels of this product.
n5:proteinBinding
More than 99% of the circulating drug is bound to plasma proteins (80% to albumin).
n5:salt
n15:hasConcept
n16:M0228730
foaf:page
n11:cerivastatin.html n17:cerivastat.htm
n5:IUPAC-Name
n8:271B4EF7-363D-11E5-9242-09173F13E4C5
n5:InChI
n8:271B4EFD-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n8:271B4EFC-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n8:271B4EF9-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n8:271B4EFA-363D-11E5-9242-09173F13E4C5
n5:SMILES
n8:271B4EFB-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n8:271B4EF5-363D-11E5-9242-09173F13E4C5 n8:271B4F0D-363D-11E5-9242-09173F13E4C5
n5:logP
n8:271B4EF3-363D-11E5-9242-09173F13E4C5 n8:271B4EF6-363D-11E5-9242-09173F13E4C5 n8:271B4F0E-363D-11E5-9242-09173F13E4C5
n5:logS
n8:271B4EF4-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count
n8:271B4F03-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n8:271B4F04-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n8:271B4EFE-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n8:271B4EFF-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n8:271B4F01-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n8:271B4F00-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n8:271B4F02-363D-11E5-9242-09173F13E4C5
n5:absorption
The mean absolute oral bioavailability 60% (range 39 - 101%).
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
145599-86-6
n5:category
n5:Bioavailability
n8:271B4F09-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n8:271B4F0B-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n8:271B4F0C-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n8:271B4F08-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n8:271B4F07-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n8:271B4F0A-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n8:271B4EF8-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n8:271B4F05-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n8:271B4F06-363D-11E5-9242-09173F13E4C5